10 results about "Schizandrol A" patented technology

The invention discloses a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease as well as a preparation and application thereof, and belongs to the technical field of chronic obstructive pulmonary disease medicines. The traditional Chinese medicine composition consists of a qi tonifying component, a blood activating component and a phlegm reducing component, or consists of the qi tonifying component and the blood activating component, or consists of the qi tonifying component and the phlegm reducing component, wherein the qi-tonifying component is selected from any one or a combination of more of ginsenoside Rg1, ginsenoside Rb1, astragaloside and schizandrin; the blood activating component is selected from any one or combination of more of ligustrazine and ferulic acid; the phlegm reducing component is selected from any one or combination of more of glucosinolate and quercetin. The compatibility and combination of the medicines have obvious effects in the aspects of improving lung inflammatory response and inhibiting pathological remodeling of pulmonary blood vessels.

The application discloses a quality detection method for a compound phyllium panax schisandra preparation, and belongs to the technical field of drug detection and analysis. The traditional Chinese medicine is composed of phyllium, panax and schisandra. Qualitative analysis is conducted on the phyllium, panax and schisandra in the compound by using a thin layer chromatography method; and the contents of gallic acid, ginsenoside Rg1 and schisandrin A in the compound are determined by using a high performance liquid chromatography method. The thin layer chromatography method is one of classical traditional Chinese medicine analysis methods, and has the advantages of rapidness, convenience and the like; the high performance liquid chromatography method is also one of classical traditional Chinese medicine analysis methods, and has the advantages of mature technology, good stability, high universality and the like, can be used for widely and accurately detecting chemical components in a complex traditional Chinese medicine compound, the content determination method passes the method validation, has good linear relationship, and the precision, stability, repeatability and recovery rate meet the regulations, and the combination of qualitative analysis and quantitative analysis lays a foundation for establishing the quality standard of the compound preparation.

The invention discloses a quality detection method of a compound phyllanthus emblica, ginseng and schisandra chinensis preparation, and belongs to a medicine detection and analysis technology. The traditional Chinese medicine is composed of emblic leafflower fruit, ginseng and Chinese magnoliavine fruit. Carrying out qualitative analysis on the emblic leafflower fruit, the ginseng and the Chinese magnoliavine fruit in the compound by using a thin layer chromatography; and determining the contents of gallic acid, ginsenoside Rg1 and schizandrin in the compound by using a high performance liquid chromatography. The thin-layer chromatography is one of classical traditional Chinese medicinal material analysis methods, and has the advantages of rapidness, convenience and the like; the high performance liquid chromatography is also one of classical traditional Chinese medicinal material analysis methods, has the advantages of mature technology, good stability, high universality and the like, can be used for widely and accurately detecting the chemical components in the complex traditional Chinese medicinal compound, passes methodology verification, and is good in linear relation and high in accuracy. The precision, the stability, the repeatability, the recovery rate and the like all meet regulations, and the combination of qualitative analysis and quantitative analysis lays a foundation for the establishment of the quality standard of the compound preparation.

The invention discloses a preparation method and application of composite freeze-dried powder based on inonotus obliquus, and relates to the technical field of biological product preparation. The invention aims to solve the problems that the extraction efficiency and the extraction rate of effective components in inonotus obliquus are low, the stability and the activity of the effective components are difficult to maintain, and the provision condition is harsh due to low solubility of schisandra chinensis. According to the inonotus obliquus composite freeze-dried powder prepared by compounding the fructus schisandrae chinensis extract and the amomum tsao-ko alcohol extract by adopting the process disclosed by the invention, the content of crude polysaccharide is increased by 27.67%, the content of inonotus obliquus polysaccharide is increased by 23.2%, the content of beta-glucan is increased by 14.28%, the content of triterpenoids is increased by 26.2%, the content of schizandrin is increased by 40%, and the content of fructus schizandrin is increased by 20%. The compound has the potential of being used for preparing drugs with high curative effects, such as tumor resistance, blood sugar reduction, blood pressure reduction, virus resistance and aging resistance. The invention can obtain the preparation method and the application of the inonotus obliquus-based composite freeze-dried powder.

The application discloses a capsule for assisting in protecting chemical liver injury and a preparation method thereof, and belongs to the technical field of health-care food. The capsule is composed of curcuma longa extract 100g, silybum marianum extract 70g, schisandra chinensis extract 60g, microcrystalline cellulose 109.5g, silicon dioxide 7g and magnesium stearate 3.5g, and 1000 capsules are taken as a unit. The curcuma longa extract contains curcumin, the content of which is greater than or equal to 10% (10:1), the silybum marianum extract contains silybin, the content of which is greater than or equal to 20% (25:1), and the schisandra chinensis extract contains schisandrin, the content of which is greater than or equal to 1.5% (12.5:1). The three kinds of plant extracts are scientifically compounded, and the effects of antioxidation, anti-inflammation, liver cell membrane protection and bile secretion regulation are synergistically exerted. Through systematic screening of the types and dosages of the filling agent, the flow agent and the lubricant, the technical problems of poor flowability of the mixed plant extract powder, large filling difference and easy jamming are solved.

The invention discloses a quality control method of sugar-free qi-tonifying and body-building granules, and belongs to the technical field of traditional Chinese medicine preparation inspection, HPLC is used for analyzing the content of schizandrin in the qi-tonifying and body-building granules, and the quality control method comprises the following steps: S1, sample pretreatment, S2, preparation of a test solution and a reference solution, and S3, sample detection by HPLC; the method comprises the following steps: S1, preparing a sample solution from a sample with water, adding a urea solution, polyethylene glycol 4000 and Tween-80, and carrying out gradient separation and reverse vacuum concentration through a temperature-sensitive composite membrane system to obtain a concentrated solution; the invention discloses an inspection condition of HPLC (High Performance Liquid Chromatography). A temperature-sensitive composite membrane system comprises a functional layer and a supporting layer, wherein the functional layer is formed by a polyvinylidene fluoride membrane grafted with polyisopropylacrylamide; the supporting layer is obtained by weaving polyester fibers modified by a silane coupling agent KH-550 in a gradient manner; according to the method, the interference of stevioside, dextrin and cellulose raw materials on a test result is eliminated, and the difficulty in quantifying schizandrin in sugar-free granules is overcome.

This application relates to the field of traditional Chinese medicine preparations and discloses a Guanxin Shengmai Pill, comprising the following ingredients, by weight: 7-12 parts ginseng, 7-12 parts ophiopogon, 2-5 parts schisandra chinensis, 12-20 parts salvia miltiorrhiza, 10-15 parts red peony root, 7-12 parts curcuma, and 0.4-0.8 parts Panax notoginseng powder. The following excipients, based on the total weight of the medicinal materials, are also included: 0.2%-0.5% xanthan gum, 0.1%-0.3% chitosan, 1%-2% β-cyclodextrin, and 30%-50% refined honey. By employing a dual-phase extraction technique combining water-soluble and fat-soluble extraction, and by performing segmented extractions tailored to the characteristics of water-soluble components (such as ginsenosides and tanshinones) and fat-soluble components (such as schisandrin A and curcumin), the invention incorporates adsorption purification and molecular distillation techniques to achieve a 30%-40% increase in the extraction rate of key active ingredients while reducing impurity interference, addressing issues such as insufficient active ingredient content and unstable efficacy.

This invention provides a *Bacillus hygroscopicus* strain and its application, relating to the field of microbial fermentation technology. The strain is named *Bacillus hygroscopicus* (…). Bacillus altitudinis Bacillus subtilis (W09), deposited at the China General Microbiological Culture Collection Center (CGMCC), located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, China, Institute of Microbiology, Chinese Academy of Sciences, on December 26, 2025, with accession number CGMCC No. 37218. This invention provides Bacillus subtilis (W09). Bacillus altitudinis W09 can be used to increase the content of schisandrol A in the fermentation products of Schisandra chinensis vine stems.

The present invention discloses a traditional Chinese medicine composition for treating chronic obstructive pulmonary disease, its preparation and application, and belongs to the technical field of COPD drugs. The traditional Chinese medicine composition is composed of a qi-invigorating component, a blood-activating component and a phlegm-resolving component, or a qi-invigorating component and a blood-activating component, or a qi-invigorating component and a phlegm-resolving component; wherein the qi-invigorating component is selected from any one or more combinations of ginsenoside Rg1, ginsenoside Rb1, astragaloside IV, and schisandrin A; the blood-activating component is selected from any one or more combinations of ligustrazine and ferulic acid; and the phlegm-resolving component is selected from any one or more combinations of sinigrin and quercetin. The combination of the above drugs has a significant effect on improving lung inflammatory response and inhibiting pathological remodeling of pulmonary vascular.

This invention discloses a method for determining the content of codonopsis glycosides in Shengmai Yin soft capsules, belonging to the field of traditional Chinese medicine preparation quality testing technology. The method employs high-performance liquid chromatography (HPLC) with octadecylsilane-bonded silica gel as the packing material, methanol-water (40:60) as the mobile phase, a detection wavelength of 267 nm, and a column temperature of 40℃. The test sample is prepared by reflux of 30% methanol for 30 minutes. Method validation showed that codonopsis glycosides exhibited good linearity in the range of 0.02608 μg–0.28688 μg (r = 0.9999). The instrument precision, repeatability, stability, and recovery rate all met the requirements for quantitative analysis, and the negative control showed no interference. This method is highly specific, simple to operate, and provides accurate and reliable results. It enables precise control of the key components of the principal herb, Codonopsis pilosula, overcoming the shortcomings of the original standard which only determined schisandrol A. It is suitable for quality control, production process optimization, and product quality improvement of Shengmai Yin soft capsules.